Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 12, 2025DiseasesOpen Access

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

EAElisavet ApostolidouVGVasileios GeorgoulisDLDimitrios Leonardos

Discussion

Loading...

Member takes

Overview

This review evaluates the molecular pathogenesis and new complement inhibitors in paroxysmal nocturnal hemoglobinuria, highlighting ongoing challenges in treatment.

Key Points

  • New therapies target proximal complement components, improving management of paroxysmal nocturnal hemoglobinuria.
  • The complement inhibitor eculizumab reduces thrombotic risk but doesn't fully address anemia from extravascular hemolysis.
  • Somatic mutations in the PIGA gene lead to the absence of critical complement regulators in patients with paroxysmal nocturnal hemoglobinuria.
  • Pathophysiology and emerging treatment options for paroxysmal nocturnal hemoglobinuria are crucial for advancing patient care.

Cite This Study

Apostolidou et al. (2025) studied this question.

synapsesocial.com/papers/68d41ee1713b0b5dfea681dehttps://doi.org/10.3390/diseases13090298
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies2025
  2. 2Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition2025 · 1 citations
  3. 3[New treatment strategies for paroxysmal nocturnal hemoglobinuria: drug selection in the era of novel complement inhibitors].2025
  4. 4CLINICAL SPECTRUM AND THERAPEUTIC ADVANCES IN PEDIATRIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA2025
  5. 5Paroxysmal nocturnal hemoglobinuria masquerading as hemolytic uremic syndrome: a Case Report2025